IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV). BiondVax’s pipeline is based on an innovative platform technology of alpaca-derived nanosized antibodies, known as Nanobodies or NanoAbs, addressing infectious and autoimmune diseases with large unmet medical needs such as COVID-19, psoriasis, psoriatic arthritis, asthma and macular degeneration.
This appearance follows a December 2022 interview between Reichman and host Stuart Smith. To review the first part of the series, visit The Stock2Me Podcast.
To begin the latest interview, Reichman discussed the company’s recent achievements, as detailed in a letter to shareholders issued late last year.
“At the end of 2022, we did a round of financing and raised about $8 million. We also started the negotiations to in-license the next antibody from the Max Planck Institute – namely the antibody for targeting interleukin-17 (IL-17) for the treatment of psoriasis,” Reichman said. “We have now in-licensed the IL-17 nanobody. This is a highly promising drug.”
“If we look at the market, psoriatic patients today have several options for treatment. For example, plaque psoriasis patients have creams and other topical drugs, biologics and oral drugs… The topicals are not highly sophisticated drugs to say the least, and they come with a considerable profile of side effects. When a person needs to take steroids once in a while for an infection, they can tolerate it, but when you need to take steroids for an autoimmune disease with chronic inflammation, you create tolerance and deal with potential side effects… The biologics are highly potent, but they are restricted to moderate and severe cases of psoriasis; this accounts for only 15% of patients with psoriasis. The 85% that are left have to choose between drugs based on 1960s and 1970s technology. There hasn’t been much breakthrough in recent years to serve these patients.”
“When you are talking about autoimmune disease, you are talking about chronic disease. Therefore, the patient should use this drug for life… The total [annual] sales of anti-interleukin-17 monoclonal antibodies are about $7.5 billion. If you take all of the other psoriasis biologics, the market is about $10 billion per year, targeting only severe cases. What we want to do is generate an axis for a highly potent, highly specific drug that’s safe to use for mild-to-moderate psoriasis cases. This is where our nanobodies are the best fit… We can inject it in an affordable way directly to the lesion… to provide relief and alleviate inflammation. Then, the next treatment will come only with the next flareup, six months or a year later.”
The company expects to complete a proof-of-concept trial later this year, followed later by human clinical trials.
Join IBN’s Stuart Smith and Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), to learn more about the company’s efforts to address the underserved mild-to-moderate psoriasis treatment market by leveraging its novel NanoAbs platform.
To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 17 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
BiondVax Pharmaceuticals Ltd. is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information, visit the company’s website at www.BiondVax.com
IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.